Riems/Berlin, 05. September 2016 – The contractual agreement signed at the end of August ushers in the takeover by RIEMSER Pharma GmbH of the entire CNS portfolio from Dolorgiet GmbH & Co. KG.
The portfolio includes established brands such as the antidepressant Anafranil® (Clomipramine), the hypnotic agent Staurodorm® (Flurazepam) and the anti-migraine preparation Migränerton® (Paracetamol & Metoclopramide). Anafranil® is used in several areas of treatment, such as for depressive disorders, obsessive compulsive disorders, phobias and panic disorders. Staurodorm® is a hypnotic agent belonging to the group of benzodiazepines and is used for the short-term treatment of insomnia. The combination preparation Migränerton® is used to treat headaches accompanied by the dizziness, nausea and vomiting associated with migraine attacks. As an expert in specialist therapeutics, RIEMSER Pharma GmbH is expanding its business activity through this acquisition by adding an important therapeutic field and opening up new growth opportunities. Konstantin von Alvensleben, Chairman of the Board of RIEMSER Pharma GmbH, comments on the acquisition as follows:
"The acquisition of the CNS portfolio is a strategic move on our part that forms the basis for further expansion in this therapeutic field."
The close collaboration that exists between the two companies will allow for the smooth transaction of the portfolio during the transitional phase.
About RIEMSER Pharma GmbH
Established in December 1992, RIEMSER Pharma GmbH is an expert in specialist therapeutics for significant unmet medical needs.
The company offers a proprietary product portfolio, which covers different therapeutic fields ranging from oncology and neuroscience to infectious diseases and dermatology. It purchases, licenses, markets and distributes pharmaceutical products. Over 300 approvals worldwide, of which 30 took place in the last two years, are a testament to the company's profound knowledge of the market.
By making strategic acquisitions in Europe, RIEMSER continues to further increase its expertise and competence in its core markets. The company has been growing sustainably for years thanks to its focus on non-cyclical segments in the pharmaceutical market. Not least because of this is RIEMSER the perfect partner for international companies who seek to access the European Market with their pharmaceutical products.
RIEMSER has its headquarters in Germany (Riems, Berlin, Greifswald, Schiffweiler) and has subsidiaries located in France (Paris) and the UK (London). The company employs more than 230 staff throughout Europe. RIEMSER was purchased in 2012 by the French Private Equity Group Ardian.
Ardian was founded in 1996 by Dominique Senequier, who still runs the company today. As an independent investment company, Ardian today manages assets worth approximately US $50 billion for its investors from Europe, North America and Asia. The company promotes business growth worldwide, thus creating sustainable returns for its investors. Ardian is aligned to the three guiding principles of excellence, loyalty and entrepreneurship and is majority owned by its employees. More than 80 percent of them have investments in Ardian, which is a testament to their confidence in the long-term strategy of the company.
Ardian has a global network of some 350 employees based at ten offices in Frankfurt, Jersey, London, Luxembourg, Milan, New York, Paris, Beijing, Singapore and Zurich. Ardian offers a full range of alternative asset classes for its some 355 investors: Fund of Funds (umbrella fund: Primary, Early Secondary and Secondary), Direct Funds (investment funds: Mid Cap Buyout, Expansion, Infrastructure, Ardian Growth and Co-Investment) and Private Debt (alternative financing).
RIEMSER Pharma GmbH